>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
EZH2抑制剂影响膀胱癌细胞活性及侵袭能力的研究
作者:王奕铎1 2  凌志新1  陈明1 2 
单位:1. 东南大学 医学院, 江苏 南京 210009;
2. 东南大学附属中大医院 泌尿外科, 江苏 南京 210009
关键词:膀胱癌 细胞活性 侵袭能力 EZH2抑制剂 GSK126 小鼠 
分类号:R737.14
出版年·卷·期(页码):2018·37·第三期(484-488)
摘要:

目的:探讨EZH2抑制剂GSK126对膀胱癌细胞活性及侵袭能力的影响。方法:通过膀胱癌细胞活性实验以及小鼠膀胱癌模型验证GSK126对膀胱癌细胞活性及小鼠膀胱癌肿瘤组织生长的影响,通过RT-PCR和蛋白质印迹法检测膀胱癌细胞上皮间质标记蛋白表达量来验证GSK126对膀胱癌细胞侵袭能力的影响。结果:细胞活性实验证实GSK126可以有效抑制膀胱癌细胞的活性和小鼠膀胱癌组织的生长。病理检查显示GSK126降低了小鼠膀胱癌组织的侵袭能力。体外实验显示,GSK126升高CDH1、UPK3KA的表达量,降低CDH2、ZEB1的表达量。结论:EZH2抑制剂GSK126在体内及体外实验中可抑制膀胱癌细胞的活性,降低膀胱癌细胞浸润和侵袭能力。

参考文献:

[1] WALKER N F,GAN C,OLSBURGH J,et al.Diagnosis and management of intradiverticular bladder tumours[J].Nat Rev Urol,2014,11(7):383-390.
[2] KAPLAN A L,LITWIN M S,CHAMIE K.The future of bladder cancer care in the USA[J].Nat Rev Urol,2014,11(1):59-62.
[3] BUTTIGLIERO C,TUCCI M,VIGNANI F,et al.Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer[J].Cancer Treat Rev,2017,54:1-9.
[4] van KESSEL K E,ZUIVERLOON T C,ALBERTS A R,et al.Targeted therapies in bladder cancer:an overview of in vivo research[J].Nat Rev Urol,2015,12(12):681-694.
[5] Cancer Genome Atlas Research N.Comprehensive molecular characterization of urothelial bladder carcinoma[J].Nature,2014,507(7492):315-322.
[6] WARRICK J I,RAMAN J D,KAAG M,et al.Enhancer of zeste homolog 2(EZH2) expression in bladder cancer[J].Urol oncol,2016,34(6):251-256.
[7] PRASANTH S G,PRASANTH K V.Easy stress relief by EZH2[J].Cell,2016,167(7):1678-1680.
[8] MELLING N,THOMSEN E,TSOURLAKIS M C,et al.Overexpression of enhancer of zeste homolog 2(EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre-and postoperatively assessed clinicopathological parameters[J].Carcinogenesis,2015,36(11):1333-1340.
[9] INARI H,SUGANUMA N,KAWACHI K,et al.Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer:exploratory study using primary and paired metastatic lesions[J].BMC Cancer,2017,17(1):160.
[10] MORERA L,LUBBERT M,JUNG M.Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy[J].Clin epigenetics,2016,8:57.
[11] ALFORD S H,TOY K,MERAJVER S D,et al.Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression[J].Breast Cancer Res Treat,2012,132(2):429-437.
[12] CHASE A,CROSS N C.Aberrations of EZH2 in cancer[J].Clin Cancer Res,2011,17(9):2613-2618.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 237988 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364